CK Isoforms

Purchase on Springer.com

$29.95 / €24.95 / £19.95*

* Final gross prices may vary according to local VAT.

Get Access

Abstract

In 1985, the TIMI* study group (1) conducted a 5-yr multicenter trial. The study concluded that patients with acute myocardial infarction (AMI) received maximum benefits when they received thrombolytic therapy within 4–6 h after onset of chest pain. Therefore, an early biochemical marker of AMI is crucial in diagnosis of myocardial injury. Currently, CK-MB isoforms are the only cardiac-specific markers satisfying these criteria, although other markers are being developed (see Chapter 17). The proceeding discussion is focused on review of pertinent biochemistry, approaches to analytical measurements, and the clinical applications of CK isoforms.